ChemicalBook > CAS DataBase List > Ozanezumab
Ozanezumab
- Product Name
- Ozanezumab
- CAS No.
- 1310680-64-8
- Chemical Name
- Ozanezumab
- Synonyms
- Ozanezumab;Research Grade Ozanezumab;Research Grade Ozanezumab(DHK06701)
- CBNumber
- CB48080875
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Ozanezumab Chemical Properties,Usage,Production
Uses
Ozanezumab (GSK1223249) is an anti-Nogo-A (neurite outgrowth inhibitor A) monoclonal antibody. Ozanezumab can be used in amyotrophic lateral sclerosis (ALS) and multiple sclerosis research[1].
References
[1] Meininger V, et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 Mar;16(3):208-216. DOI:10.1016/S1474-4422(16)30399-4
Ozanezumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Ozanezumab Suppliers
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 51288865780
- sales@biosynth.com
- Country
- China
- ProdList
- 6051
- Advantage
- 58
1310680-64-8, OzanezumabRelated Search:
Mosunetuzumab
Otelixizumab
catumaxomab
Inebilizumab
rafivirumab
Aprutumab
Ublituximab
Ligelizumab
Enokizumab
VeltuzuMab